NVO: financial statements from SEC — TradeAlmanac

NVO

Novo Nordisk A/S: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	309.06bn	290.40bn	232.26bn	176.95bn
Cost of revenue	58.79bn	44.52bn	35.77bn	28.45bn
Gross profit	250.28bn	245.88bn	196.50bn	148.51bn
Research and development	52.04bn	48.06bn	32.44bn	24.05bn
Operating income	127.66bn	128.34bn	102.57bn	74.81bn
Pre-tax income	130.54bn	127.19bn	104.67bn	69.06bn
Income tax	28.11bn	26.20bn	20.99bn	13.54bn
Net income	102.43bn	100.99bn	83.68bn	55.53bn
Earnings per share	23.06	22.67	18.67	12.26
Earnings per share, diluted	23.03	22.63	18.62	12.22

Balance sheet

Metric	Aug 18, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash and equivalents	—	26.46bn	15.66bn	14.39bn	12.65bn	10.72bn
Receivables	—	70.86bn	71.95bn	64.77bn	—

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating cash flow	119.10bn	120.97bn	108.91bn	78.89bn
Capital expenditure	60.14bn	47.16bn	25.81bn	12.15bn
Investing cash flow	−79.16bn	−128.90bn	−43.89bn	−24.92bn
Dividends paid

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)